Lumos Pharma (NASDAQ:LUMO) just reported results for the fourth quarter of 2023.
- Lumos Pharma reported earnings per share of -$1.17. This was below the analyst estimate for EPS of -$1.15.
- The company reported revenue of $826,000.
Please enter the email address associated with your account and we'll send you a magic link for a password-free sign in.
The provided email address must be associated with an account to receive a login link. If you can't find the email, please check your spam folder.
Enter your existing account details once to link them to this sign-in method.
Not Yet a Premium Subscriber?
Subscribe